|
1
|
Goldman JM: Ponatinib for chronic myeloid
leukemia. N Engl J Med. 367:2148–2149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gromicho M, Dinis J, Magalhaes M, et al:
Development of imatinib and dasatinib resistance: dynamics of
expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and
SLC22A1. Leuk Lymphoma. 52:1980–1990. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Breccia M and Alimena G: Refining targeted
therapies in chronic myeloid leukemia: development and application
of nilotinib, a step beyond imatinib. Onco Targets Ther. 1:49–58.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shah NP, Nicoll JM, Nagar B, et al:
Multiple BCR-ABL kinase domain mutations confer polyclonal
resistance to the tyrosine kinase inhibitor imatinib (STI571) in
chronic phase and blast crisis chronic myeloid leukemia. Cancer
Cell. 2:117–125. 2002. View Article : Google Scholar
|
|
5
|
Cortes JE, Kantarjian H, Shah NP, et al:
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
N Engl J Med. 367:2075–2088. 2012. View Article : Google Scholar
|
|
6
|
Jones PM and George AM: The ABC
transporter structure and mechanism: perspectives on recent
research. Cell Mol Life Sci. 61:682–699. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davidson AL, Dassa E, Orelle C and Chen J:
Structure, function, and evolution of bacterial ATP-binding
cassette systems. Microbiol Mol Biol Rev. 72:317–364. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun YL, Patel A, Kumar P and Chen ZS: Role
of ABC transporters in cancer chemotherapy. Chin J Cancer.
31:51–57. 2012. View Article : Google Scholar
|
|
9
|
Szakacs G, Varadi A, Ozvegy-Laczka C and
Sarkadi B: The role of ABC transporters in drug absorption,
distribution, metabolism, excretion and toxicity (ADME-Tox). Drug
Discov Today. 13:379–393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brozik A, Hegedus C, Erdei Z, et al:
Tyrosine kinase inhibitors as modulators of ATP binding cassette
multidrug transporters: substrates, chemosensitizers or inducers of
acquired multidrug resistance? Expert Opin Drug Metab Toxicol.
7:623–642. 2011. View Article : Google Scholar
|
|
11
|
Hegedus T, Orfi L, Seprodi A, Varadi A,
Sarkadi B and Keri G: Interaction of tyrosine kinase inhibitors
with the human multidrug transporter proteins, MDR1 and MRP1.
Biochim Biophys Acta. 1587:318–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozvegy-Laczka C, Hegedus T, Varady G, et
al: High-affinity interaction of tyrosine kinase inhibitors with
the ABCG2 multidrug transporter. Mol Pharmacol. 65:1485–1495. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hegedus C, Ozvegy-Laczka C, Apati A, et
al: Interaction of nilotinib, dasatinib and bosutinib with ABCB1
and ABCG2: implications for altered anti-cancer effects and
pharmacological properties. Br J Pharmacol. 158:1153–1164. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burger H, van Tol H, Boersma AW, et al:
Imatinib mesylate (STI571) is a substrate for the breast cancer
resistance protein (BCRP)/ABCG2 drug pump. Blood. 104:2940–2942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brendel C, Scharenberg C, Dohse M, et al:
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity
interaction with ABCG2 on primitive hematopoietic stem cells.
Leukemia. 21:1267–1275. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen T, Kuang YH, Ashby CR, et al:
Imatinib and nilotinib reverse multidrug resistance in cancer cells
by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One.
4:e75202009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tiwari AK, Sodani K, Wang SR, et al:
Nilotinib (AMN107, Tasigna) reverses multidrug resistance by
inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR
transporters. Biochem Pharmacol. 78:153–161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tiwari AK, Sodani K, Dai CL, et al:
Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-,
ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer
Lett. 328:307–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dai CL, Tiwari AK, Wu CP, et al: Lapatinib
(Tykerb, GW572016) reverses multidrug resistance in cancer cells by
inhibiting the activity of ATP-binding cassette subfamily B member
1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuang YH, Shen T, Chen X, et al: Lapatinib
and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated
multidrug resistance. Biochem Pharmacol. 79:154–161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sen R, Natarajan K, Bhullar J, et al: The
novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of
the MDR-associated ATP-binding cassette transporter ABCG2. Mol
Cancer Ther. 11:2033–2044. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Malofeeva EV, Domanitskaya N, Gudima M and
Hopper-Borge EA: Modulation of the ATPase and transport activities
of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer
Res. 72:6457–6467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hopper-Borge EA, Churchill T, Paulose C,
et al: Contribution of Abcc10 (Mrp7) to in vivo paclitaxel
resistance as assessed in Abcc10−/− mice. Cancer Res.
71:3649–3657. 2011.PubMed/NCBI
|
|
24
|
Chen ZS, Hopper-Borge E, Belinsky MG,
Shchaveleva I, Kotova E and Kruh GD: Characterization of the
transport properties of human multidrug resistance protein 7 (MRP7,
ABCC10). Mol Pharmacol. 63:351–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carmichael J, DeGraff WG, Gazdar AF, Minna
JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: assessment of chemosensitivity testing. Cancer
Res. 47:936–942. 1987.PubMed/NCBI
|
|
26
|
Zhou Y, Hopper-Borge E, Shen T, et al:
Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated
multidrug resistance. Biochem Pharmacol. 77:993–1001. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi Z, Liang YJ, Chen ZS, et al: Reversal
of MDR1/P-glycoprotein-mediated multidrug resistance by
vector-based RNA interference in vitro and in vivo. Cancer Biol
Ther. 5:39–47. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van den Heuvel-Eibrink MM, van der Holt B,
Burnett AK, et al: CD34-related coexpression of MDR1 and
BCRP indicates a clinically resistant phenotype in patients
with acute myeloid leukemia (AML) of older age. Ann Hematol.
86:329–337. 2007.PubMed/NCBI
|
|
29
|
Wulf GG, Wang RY, Kuehnle I, et al: A
leukemic stem cell with intrinsic drug efflux capacity in acute
myeloid leukemia. Blood. 98:1166–1173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lainey E, Sebert M, Thepot S, et al:
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Cell Cycle. 11:4079–4092. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Steinbach D and Legrand O: ABC
transporters and drug resistance in leukemia: was P-gp nothing but
the first head of the Hydra? Leukemia. 21:1172–1176. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schaich M, Soucek S, Thiede C, Ehninger G
and Illmer T: MDR1 and MRP1 gene expression are
independent predictors for treatment outcome in adult acute myeloid
leukaemia. Br J Haematol. 128:324–332. 2005. View Article : Google Scholar
|
|
33
|
List AF, Kopecky KJ, Willman CL, et al:
Benefit of cyclosporine modulation of drug resistance in patients
with poor-risk acute myeloid leukemia: a Southwest Oncology Group
study. Blood. 98:3212–3220. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Coley HM: Overcoming multidrug resistance
in cancer: clinical studies of P-glycoprotein inhibitors. Methods
Mol Biol. 596:341–358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van der Holt B, Lowenberg B, Burnett AK,
et al: The value of the MDR1 reversal agent PSC-833 in addition to
daunorubicin and cytarabine in the treatment of elderly patients
with previously untreated acute myeloid leukemia (AML), in relation
to MDR1 status at diagnosis. Blood. 106:2646–2654. 2005.PubMed/NCBI
|
|
36
|
Tang R, Faussat AM, Perrot JY, et al:
Zosuquidar restores drug sensitivity in P-glycoprotein expressing
acute myeloid leukemia (AML). BMC Cancer. 8:512008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cortes JE, Pinilla-Ibarz J, le Coutre P,
Paquette R, Chuah C, Nicolini FE, Apperley J and Khoury HJ: A
pivotal phase 2 trial of ponatinib in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ALL) resistant or intolerant to
dasatinib or nilotinib, or with the T315I BCR-ABL mutation:
12-Month Follow-up of the PACE Trial J, 2012. https://ash.confex.com/ash/2012/webprogram/Paper48561.html.
|
|
38
|
Niu Q, Wang W, Li Y, et al: Low molecular
weight heparin ablates lung cancer cisplatin-resistance by inducing
proteasome-mediated ABCG2 protein degradation. PLoS One.
7:e410352012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Han HK and Van Anh LT: Modulation of
P-glycoprotein expression by honokiol, magnolol and
4-O-methylhonokiol, the bioactive components of Magnolia
officinalis. Anticancer Res. 32:4445–4452. 2012.PubMed/NCBI
|
|
40
|
Tang SL, Chen WJ, Yin K, et al: PAPP-A
negatively regulates ABCA1, ABCG1 and SR-B1 expression by
inhibiting LXRα through the IGF-I-mediated signaling pathway.
Atherosclerosis. 222:344–354. 2012.PubMed/NCBI
|
|
41
|
Wang H, Wang X, Li Y, et al: The
proteasome inhibitor bortezomib reverses P-glycoprotein-mediated
leukemia multi-drug resistance through the NF-κB pathway.
Pharmazie. 67:187–192. 2012.PubMed/NCBI
|
|
42
|
Wang P, Zhang Z, Gao K, et al: Expression
and clinical significance of ABCC10 in the patients with non-small
cell lung cancer. Zhongguo Fei Ai Za Zhi. 12:875–878. 2009.(In
Chinese).
|
|
43
|
Oguri T, Ozasa H, Uemura T, et al:
MRP7/ABCC10 expression is a predictive biomarker for the resistance
to paclitaxel in non-small cell lung cancer. Mol Cancer Ther.
7:1150–1155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Borel F, Han R, Visser A, et al: Adenosine
triphosphate-binding cassette transporter genes up-regulation in
untreated hepatocellular carcinoma is mediated by cellular
microRNAs. Hepatology. 55:821–832. 2012. View Article : Google Scholar
|
